Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Aquestive Therapeutics Inc (NASDAQ: AQST) closed at $3.52 down -1.95% from its previous closing price of $3.59. In other words, the price has decreased by -$1.95 from its previous closing price. On the day, 0.71 million shares were traded. AQST stock price reached its highest trading level at $3.64 during the session, while it also had its lowest trading level at $3.46.
Ratios:
For a deeper understanding of Aquestive Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.91 and its Current Ratio is at 6.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on December 17, 2024, initiated with a Overweight rating and assigned the stock a target price of $17.
On May 10, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $8.
On April 11, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.Piper Sandler initiated its Overweight rating on April 11, 2024, with a $10 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 26 ’24 when Jung Cassie sold 44 shares for $4.87 per share. The transaction valued at 214 led to the insider holds 0 shares of the business.
Schobel Alexander Mark sold 50,000 shares of AQST for $300,000 on Mar 15 ’24. The Chief Innovation/Tech Officer now owns 984,476 shares after completing the transaction at $6.00 per share. On Mar 08 ’24, another insider, Schobel Alexander Mark, who serves as the Chief Innovation/Tech Officer of the company, sold 25,000 shares for $5.19 each. As a result, the insider received 129,685 and left with 1,040,371 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 320947264 and an Enterprise Value of 291776416. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.34. Its current Enterprise Value per Revenue stands at 4.954 whereas that against EBITDA is -14.561.
Stock Price History:
Over the past 52 weeks, AQST has reached a high of $6.23, while it has fallen to a 52-week low of $1.95. The 50-Day Moving Average of the stock is -24.37%, while the 200-Day Moving Average is calculated to be -12.32%.
Shares Statistics:
For the past three months, AQST has traded an average of 1.51M shares per day and 1578230 over the past ten days. A total of 91.18M shares are outstanding, with a floating share count of 77.61M. Insiders hold about 14.88% of the company’s shares, while institutions hold 45.89% stake in the company. Shares short for AQST as of 1732838400 were 10150852 with a Short Ratio of 6.41, compared to 1730332800 on 10143690. Therefore, it implies a Short% of Shares Outstanding of 10150852 and a Short% of Float of 13.33.
